MetaCap

Biodesix Inc. (BDSX)

NASDAQ: BDSXHealth CareMedical SpecialitiesUSD

7.56-0.74 (-8.92%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BDSX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$83.83M
EPS (TTM)
-$2.69
52-week range
5.26 – 31.97
Day range
7.50 – 8.45
Volume / Avg
205.37K / 164.58K
Beta
—

52-week range

$5.26$31.97

BDSX stock today

Shares of Biodesix (BDSX) finished lower on Nov 20 at $7.56, a drop of 8.92% or $0.74 per share, versus the S&P 500's 3.70% decline. Shares are 76.4% below their 52-week high of $31.97, set on Sep 28, 2026 and 43.7% above the 52-week low of $5.26, near the bottom of the past year's range. BDSX is up 11.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.7%.

Biodesix has posted a net loss over the last twelve months (EPS of -$2.69), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Biodesix

Company profile

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

Industry
Medical Specialities
CEO
Mr. Scott Hutton
Headquarters
Louisville, CO
Employees
334
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Biodesix generated $88.5 million in revenue, up 24.1% from fiscal 2024, its 3rd consecutive year of revenue growth. Biodesix reported a net loss of $35.3 million, compared with a loss of $42.9 million a year earlier. Operating margin was -31.5%.

Biodesix annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$88.50M$71.32M$49.09M$38.21M$54.51M
Growth+24.08%+45.30%+28.46%-29.89%+19.64%
Net income$-35.27M$-42.93M$-52.15M$-65.45M$-43.16M
EPS (diluted)$-4.67$-6.64$-0.64$-1.55$-1.58

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$33.83+347.49%

  • Strong buy 0
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $30.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.16 vs $-0.74
Surprise
-56.76%

BDSX news

All BDSX news

Biodesix peers

Health Care sector
BDSX peer companies
CompanyPrice% ChgMarket capCompare
XGNExagen Inc.3.61-5.00%$92.10Mvs BDSX
SERASera Prognostics Inc. Class A1.81-4.23%$71.98Mvs BDSX
KEQUKewaunee Scientific Corporation33.55-2.75%$97.14Mvs BDSX
BNRBurning Rock Biotech Limited ADR13.24-0.60%$139.63Mvs BDSX
TLSITriSalus Life Sciences Inc.2.32+6.67%$143.14Mvs BDSX
MDXHMDxHealth SA0.1074-8.52%$10.25Mvs BDSX
AMSAmerican Shared Hospital Services1.00-4.76%$6.67Mvs BDSX
ACONAclarion Inc.1.22-13.92%$3.52Mvs BDSX

Indexes, lists and sector

Biodesix stock FAQ

What is Biodesix's stock price today?

BDSX last traded at $7.56 as of Nov 20, 4:00 PM EST, down 8.92% on the day. Prices are delayed at least 15 minutes.

Does Biodesix pay a dividend?

No. Biodesix does not currently pay a regular cash dividend.

Who is Biodesix's CEO?

Mr. Scott Hutton is the chief executive officer of Biodesix Inc., which has about 334 employees.

Has BDSX ever split its stock?

Yes. The most recent BDSX stock split was a 1-for-20 split on Sep 15, 2025.

What is the BDSX 52-week high?

The 52-week high for BDSX is $31.97 and the 52-week low is $5.26. The stock is currently 76.4% below its high.

Compare BDSX